In patients with grade II or grade III glioma, bevacizumab administered in combination with temozolomide confers no additional survival advantage over temozolomide alone, according to a phase II trial published in The Lancet Oncology. The open-label TAVAREC trial enrolled 155 patients who had recurrent grade II or grade III glioma without chromosome 1p and 19q co-deletion — a tumour subclass that often responds poorly to chemotherapy. The participants were randomly assigned to receive temozolomide plus bevacizumab or temozolomide alone. The addition of bevacizumab to temozolomide chemotherapy did not significantly improve overall survival or progression-free survival at 12 months, and the researchers concluded that bevacizumab does not warrant further exploration as a treatment for this glioma subclass.